The use of drugs and drug combinations targeting various bile acid-signaling molecules (FGF15/19), bile acid receptors (G protein-coupled bile acid receptor 1 (TGR5) and FGFR4), and bile acid transporters (apical sodium-dependent bile acid transporter (ASBT)) may provide novel targets in the approach to NAFLD and liver cancer [155,158,163,184]. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.